COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.
The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement.
As a result, Novo will discontinue Tresiba’s unbranded biological versions by the end of this year, it added.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
Brought to you by www.srnnews.com